vimarsana.com

Latest Breaking News On - காரா சிகிச்சை இன்க் - Page 2 : vimarsana.com

Cardiff Oncology Announces the Appointment of Two New Independent Members to its Board of Directors

Stocks Rallying on Investment Valuation: Cara Therapeutics (NASDAQ:CARA), Advaxis (NASDAQ:ADXS)

Under investment valuation analysis, Cara Therapeutics, Inc. (NASDAQ:CARA) presented as an active mover, it has floated short ration of 17.83%, hold to candle to sentiment indicator of Short Ratio, which was 2.83. Shares inched down -0.67% to trade at $17.92 in most recent trading session. The co stands at price to sale ratio of 5282.23 that signifies the value placed on each dollar of a firm’s sales or incomes; it is most relevant ratio to compare companies in similar sector. It has price to book ratio of 6.81, which gauges the market price of a share over its book value. The firm has price volatility of 7.60% for a week and 7.04% for a month. Narrow down focus to firm performance, its weekly performance was 10.55% and monthly performance was 13.13%. The stock price of CARA is moving up from its 20 days moving average with 14.55% and isolated positively from 50 days moving average with 36.18%.

Cara Therapeutics Inc (CARA) Q1 2021 Earnings Call Transcript

Operator I would now like to turn the call over to the CARA team. Please proceed. Jack Hildick-Smith Investor Relations Good afternoon, this is Jack Hildick-Smith with Stern Investor Relations and welcome to Cara Therapeutics first quarter 2021 financial results and update conference call. The news release became available just after 4:00 PM today and can be found on our website at www.caratherapeutics.com. You may also listen to a live webcast and replay of today s call on the Investors section of the website. Before we begin, let me remind you that statements made on today s call regarding matters that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of these forward-looking statements, include statements concerning the expected timing of the data readouts from the company s planned and ongoing clinical trials, the potential results of ongoing clinical trials, timing of future regul

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.